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Abstract
Since the beginning of the United States AIDS epidemic in the early 1980s, the medical
community has overcome significant challenges in the diagnosis and treatment of Human
Immunodeficiency Virus (HIV) infections. Many advancements in suppressing HIV viral loads
and maintaining healthy immune system function in HIV positive patients have been achieved
with antiretroviral therapy (ART). Moreover, these drugs have been shown to be effective for
preventing HIV infections. Once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) has
been approved by the FDA for this purpose. The availability of this preventive therapy, commonly
known as preexposure prophylaxis (PrEP), necessitates educating at-risk patient populations about
its prophylactic benefits. In order to select appropriate candidates for PrEP prophylaxis, its
efficacy in different at-risk populations needs to be determined. This investigation examines
disparities in PrEP’s efficacy among at-risk groups and proposes explanations that may guide the
medical provider in offering PrEP therapy to patients who could benefit. Additionally, current
clinical trials and studies with alternative PrEP options will be explored.
Keywords: HIV, HIV pre-exposure prophylaxis, HIV prevention, PrEP
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Introduction
According to the CDC’s 2015 HIV surveillance data, in the United States approximately
40,000 individuals seroconverted to an HIV positive status and the prevalence of HIV reached
nearly 1 million people. Notwithstanding this staggering number, the percentage of individuals
who became HIV seropositive declined by eight percent from the years 2010 to 2015.1 Improved
preventative and therapeutic measures have played a pivotal role in reducing HIV seroconversion
and infections. Despite advancements in HIV treatment and prevention, preventative strategies
including preexposure prophylaxis (PrEP) are underutilized across many medical settings. Of
particular concern are the stigma surrounding potential HIV exposures and the lack of awareness
about PrEP, both of which can impede the clinician’s efforts to educate patients who are at high
risk of HIV seroconversion.
In order to select candidates for prevention of HIV seroconversion, persons at increased
risk of HIV exposure need to be identified. According to the CDC, gay and bisexual men account
for 67% of the approximately 40,324 new HIV diagnoses made in the United States in 2016.2
Furthermore, receptive anal intercourse has a 13-fold higher risk of transmitting HIV than insertive
anal intercourse.3 Although male-to-male sexual contact puts gay and bisexual men as the
population at the highest risk of HIV seroconversion, other populations such as heterosexuals,
serodiscordant couples, and IV drug users are also at increased risk. Unprotected receptive anal
intercourse accounts for approximately 138 infections per 10,000 exposures, but needle-sharing
injection drug use accounts for approximately 63 infections per 10,000 exposures, while receptive
and insertive penile-vaginal intercourse each account for 8 infections and 4 infections per 10,000
exposures respectively.5 All of these high-risk populations may benefit from preventative
measures against HIV seroconversion. Therefore, medical providers should counsel patients
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accordingly. Besides educating patients about safe-sex practices, clinicians can offer preexposure
prophylaxis with anti-retroviral agents.
Antiretrovirals (ARV) have been shown to suppress HIV viral loads, which results in viable
CD4 T-lymphocyte counts and healthy immune system function in HIV infected patients. In
addition, when used prophylactically these medications have been shown to prevent HIV infection
in high-risk individuals. Truvada (emtricitabine/tenofovir disoproxil fumarate) was initially
approved in 2004 by the Food and Drug Administration (FDA) to be used in combination with
other ARVs in an HIV treatment regimen.4 After its success in HIV therapy was demonstrated,
this formulation of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) was studied
and approved by the FDA on July 16th, 2012 for preexposure prophylaxis (PrEP) treatment in HIV
negative patients who are at high risk of HIV seroconversion.3 When taken appropriately, PrEP
was shown to be effective for prevention of HIV seroconversion in at-risk populations. Experience
with PrEP has primarily been in the men who have sex with men (MSM) population. Although
PrEP’s overall efficacy in at-risk patients has been proven, further investigation is needed to show
its usefulness in specific at-risk groups such as heterosexuals, IV drug users, and serodiscordant
couples. In order to optimize PrEP’s effectiveness, it is important to understand its potential
benefits and limitations across all at-risk populations.
Animal Studies and Pharmacokinetics
Initial studies in animals and humans using tenofovir disoproxil fumarate (TDF) showed
that a single ARV was inadequate for prophylactic protection,6-7 although it did have a good safety
profile in humans. The need for two drug combinations for HIV prophylaxis was evident since a
single ARV was ineffective.
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The hypothesis of utilizing a two-drug regimen for HIV prophylaxis was promising and
thus further explored in animal models. Chinese rhesus macaques were challenged with simian
HIV to determine if using a two-drug combination compared to a single drug agent or no drug at
all had a better prophylactic effect against HIV transmission. These monkeys were either untreated
(control group) or treated; the treatment groups received tenofovir disoproxil fumarate (TDF),
emtricitabine (FTC), or a compounded TDF-FTC. The results revealed that monkeys treated with
a subcutaneous dose of FTC or a human equivalent dose of TDF-FTC, had a 3.8- and 7.8-fold
decreases in seroconversion rates respectively, compared to the untreated monkeys.8 This evidence
confirmed that two agents provided better prophylaxis than either a single agent or no ARV.
Success of the two-drug regimen in animals prompted human trials. The pharmacokinetic
profiles of ARVs in humans, in particular, their tissue penetrance, are especially important with
regards to using these drugs as a prophylactic option because some human tissues are exceptionally
vulnerable to transmission of HIV. In 2011, male and female volunteers were studied to determine
the concentrations of TDF and FTC in blood plasma as well as in mucosal tissues, particularly in
vulnerable tissues like rectal and vaginal mucosa. Despite a small sample size, 100-fold higher
concentrations of TDF were found in rectal tissues compared to vaginal/cervical tissues.9 Given
these results, PrEP use in certain groups may be more or less effective depending upon the tissue
exposed to the virus. After pharmacokinetic studies, PrEP research shifted to human participants
for FDA approval.
PrEP was approved after many noteworthy studies examined its safety and efficacy for
preventing HIV infection in groups that are at particularly high risk of HIV seroconversion, such
as the MSM population, transgender women who have sex with men, high-risk heterosexual men
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and women, and IV drug users. Clinical studies were necessary to determine PrEP’s efficacy across
these at-risk groups.
Men Who Have Sex with Men and PrEP: iPrEx Trial, ANRS Ipergay Study, PROUD study
A multinational, double-blind placebo-controlled known as the Preexposure Prophylaxis
Initiative, or the iPrEx trial, evaluated whether a once-daily compounded regimen of TDF-FTC
would provide adequate chemoprophylactic protection against HIV in the MSM and transgender
women who have sex with men populations. A total of 2499 HIV seronegative MSM and
transgendered women who have sex with men were assigned to either the treatment group with
TDF-FTC, or the placebo-control group. A comprehensive package of protection was also
provided to these patients through monthly visits. These visits included information on safe-sex
practices, condoms, HIV testing, and treatment of other STIs. Serum drug levels were also
measured in each of the subjects to determine adherence. The subjects were followed for a total of
3324 person-years. Results showed a 44% reduction in HIV seroconversion in the treatment group
compared to placebo. Although this value was lower than what the researchers predicted, the
discrepancy was partly explained by low adherence. In the subjects who had detectable serum drug
levels, risk of HIV seroconversion decreased by 92% compared to those subjects with poor or
undetectable levels who evidently did not adhere properly to the drug regimen. These findings
highlighted that PrEP compliance correlates with higher efficacy of the intended prophylactic
effect.10
Given the importance of adherence to PrEP, a study to address PrEP’s efficacy with ondemand use rather than once daily dosing was conducted. The ANRS Ipergay study examined
whether using PrEP on-demand, which means taking the drugs only as needed for risky sexual
behaviors, would still provide prophylactic protection in the MSM cohort. In this double-blind,
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randomized placebo-controlled study, on-demand use conditions were met when the treatment
group took two doses of TDF-FTC 2 to 24 hours prior to sexual contact, and then took additional
doses at 24 and 48 hours after the sexual contact. Risk was reduced by 86% in the treatment group
compared to the placebo group.11 Although these findings were promising, they were limited
because the number of on-demand doses taken could not exceed the maximum total daily dose
regardless of the number of sexual encounters in a day. An open-label study approximating reallife application of PrEP could correct this limitation.
PROUD was the first open-label, randomized controlled trial for PrEP, which was designed
to test efficacy in real-life situations in the MSM population. Five hundred and forty-four male
participants who had condom-less anal intercourse in the previous 90 days were enrolled in the
study across 13 sexual health clinics in England. Initially, the study called for an immediate
treatment group and a deferred treatment group, but all of those assigned to the deferred group
were eventually moved to the treatment group after evidence in concurrent studies showed PrEP
to be efficacious in HIV prevention. Findings confirmed that daily TDF-FTC provided the best
protection against HIV seroconversion, eliminating the concerns of PrEP utilization in the MSM
population in real-world settings.12
While PrEP is effective in MSM, the population at the highest risk of seroconversion, other
populations are also at risk, such as heterosexuals and IV drug users. These groups could
potentially benefit from PrEP, leading to additional research with PrEP in these patient
populations.
Heterosexuals and PrEP: Partners PrEP Trial, TDF2 Study, and FEM-PrEP Study
The Partners PrEP Trial addressed the use of antiretroviral therapy (ART) for preventing
HIV in heterosexual serodiscordant couples, otherwise known as discordant serostatus, which
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means one partner was HIV positive and the other is HIV negative. A sample of 4747 couples was
enrolled and then randomly assigned to treatment with TDF, TDF-FTC, or placebo.
Seroconversion occurred in a total of 82 subjects. 17 subjects seroconverted in the TDF group, 13
in the TDF-FTC group, and 52 in the placebo group, equating to a 67% and 75% decrease in
incidence of HIV seroconversion in the TDF and TDF-FTC groups, respectively.13 These results
were promising; however, further studies were needed in order to confirm that these prophylactic
treatments were efficacious in this group.
Additional research in sexually active heterosexuals at risk for HIV seroconversion was
assessed in the TDF2 study. This phase III, randomized, placebo-controlled clinical trial was
conducted in different cities in Botswana, which has the world’s second highest HIV
seroconversion rate.14 This trial randomly selected 1219 men and women to be assigned to either
the TDF-FTC treatment group or to the placebo group. Unfortunately, due to poor retention of the
subjects, it was stopped early. The researchers decided to perform a modified analysis of the data
they obtained, which showed an overall efficacy of 62.2% of TDF-FTC in preventing HIV
seroconversion when used in conjunction with a package of other HIV prevention tools.14 Despite
the poor subject retention, evidence in this study suggests that PrEP is effective. Nonetheless,
further studies are necessary to confirm these findings.
Since previous studies did not show successful HIV prevention in at-risk heterosexual
women, the 2012 FEM-PrEP study specifically tested PrEP’s efficacy in this population. Across
Kenya, South Africa, and Tanzania, 2129 women were enrolled. These women were randomly
assigned to receive once daily TDF-FTC (the treatment group), or a once daily placebo (the control
group). HIV seroconversion was detected in 33 women in the TDF-FTC group and in 35 women
in the placebo group, with an incidence rate of 4.7% and 5.0% respectively15. This study was also
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terminated early because PrEP was not proven to be efficacious in preventing HIV infection in
these women. The data did not show efficacy in once daily FTC-TDF, but detectable serum drug
levels were only present 28% to 37% at the time the specimens were collected, revealing that a
lack of adherence may have explained the lack of efficacy. Although adherence to prophylaxis is
vital for prevention, the pharmacokinetics of TDF-FTC limit drug concentrations in vaginal and
cervical tissues as compared to rectal tissues. This discrepancy in tissue drug concentration must
be considered when determining whether PrEP is appropriate for use in heterosexual females who
engage in unprotected coitus.
IV Drug Users and PrEP: The Bangkok Tenofovir Study
Though sexual transmission of HIV is of upmost concern, intravenous drug use and needle
sharing put individuals at high-risk of HIV seroconversion. According to the Center for Disease
Control, people who injected drugs (PWID) accounted for 9% of the nearly 40,000 new HIV
diagnoses in 2016.16 Even though this group accounts for a smaller percentage of new HIV
diagnoses, PrEP could still serve as a beneficial strategy. The 2013 Bangkok Tenofovir study, a
phase III, randomized, double-blind, placebo-controlled trial examined whether PrEP would
reduce the risk of HIV seroconversion in PWID. The 2413 participants were enrolled across 17
drug-treatment clinics in Bangkok, Thailand; 1204 participants in the treatment group were
instructed to take 300mg of once daily tenofovir disoproxil fumarate (TDF), and 1209 participants
belonged in the placebo control group. Seventeen subjects in the TDF group seroconverted to an
HIV positive status, while 33 seroconverted in the placebo-control group, equating to a 48.9%
reduction in HIV incidence.17 Whether those that seroconverted did so from their IV drug use or
from sexual intercourse was a limitation of this study. Nonetheless, PWID are at significant risk
of seroconverting and PrEP should be offered to this population.
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Side Effects and Adverse Events of PrEP
Currently, Once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) is approved
for the use of PrEP in high-risk patients. In the iPrEx study, nausea was reported in 22 patients in
the treatment group compared to 10 patients in the placebo group. Additionally, unintentional
weight loss of 5% or more was seen in 34 versus 19 patients of the treatment and placebo groups
respectively10. However, in the Partners PrEP trial no statistical differences were found in side
effects including fatigue, nausea, abdominal pain, headaches, or diarrhea13. Future research may
find drugs for HIV prophylaxis that have fewer side effects. Nonetheless, PrEP currently has only
limited and mostly mild adverse effects in comparison to the protective value it provides. When
prescribing PrEP, not only is understanding its side effects and adverse events important in
providing the proper patient education but also specific precautions should be considered.
Severe adverse reactions can occur with PrEP, for which reason cautionary measures
should be instituted. Truvada, which contains tenofovir disoproxil fumarate (TDF) and
emtricitabine (FTC), requires evaluation of a patient’s renal function before and during therapy.
TDF is excreted extensively by the kidneys and can be nephrotoxic. Poor renal function could lead
to toxic levels of the drug. Serum creatinine values can be used to determine whether a patient is
an appropriate candidate for PrEP and should be monitored periodically throughout therapy.18 In
the iPrEx trial, only one subject was dropped from the study due to an increase in serum creatinine
compared to no dropouts in the placebo group.10 In the Partners PrEP trial, six subjects were
dropped from the study due to an increase in their serum creatinine compared to no dropouts in
the placebo group.13
Another adverse reaction of TDF is loss of bone mineral density (BMD). Over the course
of a year’s therapy, TDF can cause a 1-3% decreased in BMD compared to other NRTIs.19 In the
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iPrEx trial, 13% of the participants lost more than 5% BMD of the spine compared to 6% of the
participants in the placebo group.10 Bone fractures were noted in 1.7% of the treatment group in
the iPrEx trial compared to 1.4% in the placebo group.10 In the Partners PrEP trial, 0.8% of the
treatment group experienced bone fractures compared to 0.6% in the placebo group.13 Although
BMD is affected, the benefits of PrEP exceed these relatively insignificant changes. Nonetheless,
this adverse effect should be taken into consideration for those with small stature or preexisting
osteomalacia.
Despite the current adverse effects of PrEP on the kidneys and bone mineral density,
healthy individuals typically tolerate the regimen well and do not require discontinuation due to
these adverse effects. Other antiretrovirals and regimens are being investigated for the purpose of
limiting the number of adverse events and removing the daily pill burden while still providing
prophylactic HIV protection.
The Future of PrEP
Descovy (emtricitabine/tenofovir alafenamide fumarate) is currently FDA approved for
the treatment of HIV. Similar to Truvada, it contains two NRTIs and should be used in
combination with other HIV medications to achieve viral suppression and maintain healthy CD4
counts. The differences between the two antiretrovirals are that Descovy contains the NRIT
known as tenofovir alafenamide fumarate (TAF) and Truvada contains an NRTI known as
tenofovir disproxil fumarate (TDF). Compared to TDF, TAF has less adverse renal effects and
leads to less bone mineral density loss.19 Given that less adverse effects are observed with
Descovy compared to Truvada, the DISCOVER study was initiated to determine if Descovy
could provide prophylactic protection similar to Truvada.
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DISCOVER, a current phase III randomized double-blind study that began in September
2016, is comparing Descovy against Truvada for safety and efficacy in preventing HIV
seroconversion in the MSM population. This study has 5400 participants who were randomized
into a group that is either being treated with Truvada (TDF-FTC) plus a placebo pill or treated
with Descovy (TAF-FTC) plus a placebo pill20. The participants will be blinded for at least 96
weeks, after which they will have the option to be unblinded and decide whether to continue in an
open label extension of the Descovy regimen for another 48 weeks. HIV status, bone mineral
density, serum creatinine, and side effects that the subjects experience will be monitored. This trial
is expected to be completed in July of 2021. If proven to be efficacious, Descovy could be the
new first-line therapy for PrEP. However, it still bears the pill-burden of a once-daily regimen.
In order to improve medication adherence issues and decrease overall pill burden, other
routes of PrEP administration are being investigated. Injectable routes of administering PrEP using
Cabotegravir (CAB), an integrase strand transfer inhibitor (INSTI), are being tested. CAB showed
excellent safety, tolerability, and acceptable pharmacokinetics in the HPTN 077 trial, a phase 2a
clinical trial to assess the safety and efficacy of the injectable long-acting CAB.21 Common side
effects in this study were a mild injection site reaction which caused some patients to drop out of
the study. The drug reached the appropriate drug levels in the treatment group that received an
injectable regimen of 600mg every 8 weeks after an initial 4 week loading dose21. Currently, the
HPTN 083 trial is underway that is comparing injectable CAB to the currently FDA approved
PrEP, oral Truvada, in the MSM population.22 Recruitment for this study is currently ongoing
and its completion date is yet to be determined. If the injectable CAB is proven to be as efficacious
as Truvada, it could become an option for at-risk individuals, especially those who have difficulty
with adhering to a daily regimen.
11

Running head: DOES PrEP DECREASE THE INCIDENCE OF HIV IN AT-RISK
POPULATIONS?
Conclusion
Evidence shows that Truvada for PrEP is efficacious if used in high-risk populations for
preventing HIV seroconversion, particularly in the MSM population. Although some studies did
not confirm its efficacy, a lack of adherence to PrEP could have explained the low prophylactic
effect. Less efficacy in certain populations, such as heterosexual women, may be explained by a
combination of noncompliance and also by the difference in tissue concentrations of PrEP. For
these reasons, the importance of adherence should be stressed when prescribing PrEP. Despite the
facts that PrEP is new to the medical community and its long-term efficacy is still being
investigated, it should be considered as part of the preventative package offered to at-risk
populations. In the future, research could reveal alternative drug options that would likely improve
patient’s adherence to PrEP and could offer drugs with less adverse effects than those in the
currently approved regimen.
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